|
|
BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
|
|
||
Re: other indicationsAfter looking up the drugs from this article https://invivo.pharmaintelligence.informa.com/IV005139/HCV-Patient-Access--Trek-Therapeutics-Takes-The-Road-Less-Traveled It appears to me that the most likely candidate is; VX-222: Non-nucleoside inhibitor of the HCV polymerase acquired from Vertex Pharmaceuticals. 5 Studies found https://clinicaltrials.gov/ct2/results?cond=&term=VX-222&cntry=&state=&city=&dist= Initial results against HVC were over 3log. http://www.hivandhepatitis.com/2010_conference/easl/docs/0420_2010_c.html Another possibility from the Drugs in the article. TD-6450: HCV NS5A inhibitor acquired from Theravance Biopharma 4 studies found https://clinicaltrials.gov/ct2/results?cond=&term=TD-6450&cntry=&state=&city=&dist= Initial results against HVC were over 3log. https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-announces-positive-results-phase-1-proof |
return to message board, top of board |